Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1163 - Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/Depot 120mg in the CLARINET open-label extension


10 Sep 2017


Poster display session


Neuroendocrine Tumours


Jaroslaw Cwikla


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


J.B. Cwikla1, E.M. Wolin2, M. Pavel3, A.T. Phan4, M. Raderer5, E. Sedláčková6, G. Cadiot7, J. Capdevila8, G. Rindi9, C. Lombard-Bohas10, N. Liyanage11, X. Truong Thanh12, P. Ruszniewski13, M. Caplin14

Author affiliations

  • 1 ., University of Warmia and Mazury, Olsztyn, Poland, 0000 - Olsztyn/PL
  • 2 ., Montefiore Einstein Center for Cancer Care, New York/US
  • 3 ., Universitätsklinikum Erlangen, Erlangen/DE
  • 4 Medical Oncology, University of New Mexico Cancer Center, Albuquerque/US
  • 5 Department Of Medicine I, Clinical Division Of Oncology, University Hospital, 1090 - Vienna/AT
  • 6 Department Of Oncology Of The First Faculty, Medicine and General Teaching Hospital, Prague/CZ
  • 7 Gastroenterology And Digestive Oncology, Robert‐Debré Hospital, 51092 - Reims/FR
  • 8 Gastrointestinal And Endocrine Tumor Unit, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 9 Diagnostica E Medicina Di Laboratorio, Università Cattolica del Sacro Cuore, Rome/IT
  • 10 Edouard-herriot Hospital, Hospices Civils de Lyon, Lyon/FR
  • 11 R&d Statistics, Ipsen Innovation, Les Ulis/FR
  • 12 ., Ipsen, Boulogne-Billancourt/FR
  • 13 ., Beaujon Hospital, Clichy/FR
  • 14 Neuroendocrine Tumour Unit, Royal Free Hospital, London/GB


Abstract 1163


The CLARINET core study established the antitumour activity of lanreotide Autogel 120mg/28 days (LAN) in metastatic enteropancreatic neuroendocrine tumours (NETs). The vast majority of the core study population (96%) had stable disease (SD) at baseline, but the LAN open-label extension (OLE) also included patients with progressive disease (PD; while receiving placebo [PBO] in the core study). Here, we report the final analysis of time to subsequent death/PD for patients with PD switched to LAN.


In the core study, patients with metastatic well-/moderately differentiated non-functioning enteropancreatic NETs received LAN/PBO for 96 weeks or until death/PD (RECIST 1.0). Eligible patients for the OLE (NCT00842348) had SD at core-study end or PD (with PBO only) during the core study. Adverse events (AEs) were recorded at 4-weekly visits. CT/MRI scans from OLE baseline (week 1) and every 24 weeks subsequently were assessed locally for PD (RECIST 1.0). Primary objective: long-term safety. Secondary objective: long-term efficacy, with assessments including PFS and time to subsequent death/PD (from Kaplan–Meier analyses; months approximated as 4 weeks).


89 patients were treated in both core and OLE studies (42 LAN–LAN [SD, n = 41]; 47 PBO–LAN [SD, n = 15]); 40% of the LAN–LAN vs. 47% of the PBO–LAN group had treatment-related AEs. Overall median LAN PFS, based on the intent-to-treat population (n = 101), was 38.5 months. Seven PD events (no deaths) occurred during the OLE in 15 patients entering with SD from the PBO arm of core study. In total, 32 patients with PD whilst receiving PBO in the core study entered OLE (of 59 potentially eligible); NETs were in pancreas in 17 patients, midgut in 10, hindgut in one, and of other/unknown origin in four. Of these patients, 20 had subsequent PD during the OLE and three died; median time to subsequent death/PD was 19.0 months [95% CI: 10.1; 26.7].


The final analysis of the CLARINET OLE study suggests benefit with LAN in patients who had experienced PD when receiving no NET-specific treatment (PBO), with median time to subsequent death/PD of 19 months.

Clinical trial identification


Legal entity responsible for the study

Ipsen Pharma


Ipsen Pharma


J.B. Cwikla: Travel expenses paid by Ipsen. E.M. Wolin: Advisory boards for Ipsen and Advanced Accelerator Applications. M. Pavel: Advisory boards and honoraria from Ipsen, Novartis, Pfizer and Lexicon; funding from Ipsen and Novartis for scientific research. A.T. Phan: Consultant for Ipsen and Novartis; Speaker’s bureau for Lilly, Genentech, Celgene, Lexicon, Novartis and Ipsen. M. Raderer: Honoraria from Ipsen, Novartis, Celgene, Roche and EASAI. E. Sedláčková: Consultant role for Ipsen; Speaker’s bureau for Ipsen, Novartis and Merck; funding from Ipsen and Novartis for scientific research; travel expenses paid by Ipsen, Novartis, Roche and Merck. G. Cadiot: Consultant role for Ipsen, Novartis, Advanced Accelerator Applications, and Keocyt; funding from Ipsen and Novartis for scientific research. J. Capdevila: Research, advisory role and speaker for Ipsen, Pfizer and Novartis. G. Rindi: Speaker’s bureau for Ipsen and Novartis. C. Lombard-Bohas: Consultant role for Ipsen, Pfizer and Novartis; funding from Ipsen and Novartis for scientific research. N. Liyanage, X-M. Truong Thanh: Employee of Ipsen P. Ruszniewski: Honoraria from Ipsen and Novartis; consultant role for Ipsen; Speaker’s bureau for Ipsen and Novartis; funding from Ipsen and Novartis for scientific research. M. Caplin: Honoraria from, consulted for, and participated in Speaker’s bureau for Ipsen and Novartis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.